CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, includ
Related Questions
What valuation multiple does the deal imply and how does it compare to recent similar AI/precisionāmedicine acquisitions?
How will the acquisition of Paige impact Tempus' revenue growth and earnings guidance?
Will the expanded digital pathology capabilities improve Tempus' competitive positioning and market share in the precision medicine sector?